Enzalutamide and Leuprolide Improves Metastasis-Free Survival in Non-Metastatic Prostate Cancer
A study arm from the phase 3 EMBARK trial evaluating XTANDI (enzalutamide) for the treatment of non-metastatic castration-sensitive prostate cancer (nmCSPC) with high-risk biochemical recurrence (BCR) has resulted in positive patient outcomes, according to Pfizer and Astellas Pharma. The phase 3, randomized, double-blind, placebo-controlled, multi-national EMBARK trial utilized 3 different study arms: enzalutamide plus leuprolide, placebo plus leuprolide, or enzalutamide monotherapy. A total of 1068 patients with nmCSPC who were considered high-risk BCR were enrolled and randomized to receive either enzalutamide 160 mg daily ...

Latest News

Editorial Advisory Board

Expert Interviews

Knowledge Hubs

Curated clinical content based on conditions, therapies, and technologies

Prostate Cancer
Prostate Cancer

The Uromigos

Podcasts hosted by Professors Thomas Powles, MD, and Brian Rini, MD

Conference Coverage

Live meeting highlights

Phouc T. Tran, MD, PhDASCO GU Symposium 2023 | February 24, 2023
Phouc Tran, MD, PhD, highlights the challenges of accurate risk stratification for newly diagnosed localized prostate cancer.
View More
Daniel M. Geynisman, MDASCO GU Symposium 2023 | February 23, 2023
Daniel M. Geynisman, MD, explains the results and utility of the RETAIN trial for bladder sparing in patients with MIBC.
Oncology BrothersOncology Brothers | February 22, 2023
Petros Grivas, MD, PhD, highlights the practice-changing studies that have come out of the ASCO GU 2023 Symposium.
Michael B. Atkins, MDASCO GU Symposium 2023 | February 18, 2023
Michael Atkins, MD, discusses TFS outcomes from the phase II study and argues for immunotherapy in favorable-risk patients.

Video Insights

Clinical discussions with experts in the field